José Luis
Pérez Gracia
Consultor Médico
Instituto de Biomedicina de Sevilla
Sevilla, EspañaPublications in collaboration with researchers from Instituto de Biomedicina de Sevilla (1)
2017
-
Atezolizumab as first-line treatment in cisplatin-ineligible patients with locally advanced and metastatic urothelial carcinoma: a single-arm, multicentre, phase 2 trial
The Lancet, Vol. 389, Núm. 10064, pp. 67-76